PMID- 28766166
OWN - NLM
STAT- MEDLINE
DCOM- 20180709
LR  - 20181202
IS  - 1573-4919 (Electronic)
IS  - 0300-8177 (Linking)
VI  - 438
IP  - 1-2
DP  - 2018 Jan
TI  - rhPDGF-BB combined with ADSCs in the treatment of Achilles tendinitis via 
      miR-363/PI3 K/Akt pathway.
PG  - 175-182
LID - 10.1007/s11010-017-3124-8 [doi]
AB  - To investigate the mechanism of recombinant human platelet-derived growth 
      factor-BB (rhPDGF-BB) and human adipose-derived stem cells (hADSCs) in the 
      treatment of Achilles tendinitis. Biomechanical indices of stiffness, stress, and 
      maximum load-to-failure were detected by biomechanical test. mRNA and protein 
      levels of miR-363, p-PI3K/AKT, tendon-related genes Collagen I, Scleraxis (Scx), 
      and Tenascin C (TNC) were measured by qRT-PCR and western blot. The proliferation 
      of hADSCs was accessed by MTT assay. Biomechanical indices of stiffness, stress, 
      and maximum load-to-failure, and mRNA and protein levels of tendon-related genes 
      could be improved by rhPDGF-BB or hADSCs alone, and could be further improved by 
      rhPDGF-BB + hADSCs. rhPDGF-BB and hADSCs downregulated the expression of miR-363 
      and upregulated the levels of p-PI3K/Akt, and rhPDGF-BB + hADSCs further 
      strengthened these effects. In addition, rhPDGF-BB promoted the proliferation of 
      hADSCs in vitro and upregulated the expression of tendon-related genes. miR-363 
      mimic downregulated the levels of p-PI3K/Akt, miR-363 inhibitor upregulated the 
      levels of p-PI3K/Akt, and miR-363 mimic and PI3K/Akt pathway inhibitor LY294002 
      reversed the positive effect of rhPDGF-BB on the proliferation of hADSCs, which 
      suggested that rhPDGF-BB promoted the proliferation of hADSCs via 
      miR-363/PI3K/Akt pathway. Biomechanical indices and tendon-related genes could be 
      improved by rhPDGF-BB and hADSCs. Moreover, rhPDGF-BB promoted the proliferation 
      of hADSCs via miR-363/PI3K/Akt pathway, indicating that rhPDGF-BB combined with 
      ADSCs could treat Achilles tendinitis via miR-363/PI3K/Akt pathway.
FAU - Chen, Qiao-Jie
AU  - Chen QJ
AD  - Department of Orthopaedics Surgery, Ningbo No. 2 Hospital, Zhejiang, 315010, 
      People's Republic of China.
FAU - Chen, Liang
AU  - Chen L
AD  - Department of Orthopaedics Surgery, Ningbo No. 2 Hospital, Zhejiang, 315010, 
      People's Republic of China.
FAU - Wu, Shao-Kun
AU  - Wu SK
AD  - Department of Orthopaedics Surgery, Ningbo No. 2 Hospital, Zhejiang, 315010, 
      People's Republic of China.
FAU - Wu, Yao-Jun
AU  - Wu YJ
AD  - Department of Orthopaedics Surgery, Ningbo No. 2 Hospital, Zhejiang, 315010, 
      People's Republic of China.
FAU - Pang, Qing-Jiang
AU  - Pang QJ
AD  - Department of Orthopaedics Surgery, Ningbo No. 2 Hospital, Zhejiang, 315010, 
      People's Republic of China. pqjey@sina.com.
AD  - , 41 Xibei Rd., Haishu, Ningbo, 315000, People's Republic of China. 
      pqjey@sina.com.
LA  - eng
PT  - Journal Article
DEP - 20170801
PL  - Netherlands
TA  - Mol Cell Biochem
JT  - Molecular and cellular biochemistry
JID - 0364456
RN  - 0 (Proto-Oncogene Proteins c-sis)
RN  - 1B56C968OA (Becaplermin)
SB  - IM
MH  - *Achilles Tendon
MH  - Adipose Tissue/*metabolism/pathology
MH  - Animals
MH  - Becaplermin
MH  - Disease Models, Animal
MH  - Heterografts
MH  - Humans
MH  - Proto-Oncogene Proteins c-sis/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - *Stem Cell Transplantation
MH  - Stem Cells/*metabolism/pathology
MH  - Tendinopathy/metabolism/pathology/*therapy
OTO - NOTNLM
OT  - Achilles tendinitis
OT  - PI3K/Akt pathway
OT  - hADSCs
OT  - miR-363
OT  - rhPDGF-BB
EDAT- 2017/08/03 06:00
MHDA- 2018/07/10 06:00
CRDT- 2017/08/03 06:00
PHST- 2017/05/10 00:00 [received]
PHST- 2017/07/15 00:00 [accepted]
PHST- 2017/08/03 06:00 [pubmed]
PHST- 2018/07/10 06:00 [medline]
PHST- 2017/08/03 06:00 [entrez]
AID - 10.1007/s11010-017-3124-8 [pii]
AID - 10.1007/s11010-017-3124-8 [doi]
PST - ppublish
SO  - Mol Cell Biochem. 2018 Jan;438(1-2):175-182. doi: 10.1007/s11010-017-3124-8. Epub 
      2017 Aug 1.